Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 2
1984 1
1990 2
1991 7
1992 2
1993 3
1994 1
1995 3
1996 5
1997 3
1998 2
1999 6
2000 6
2001 5
2002 7
2003 4
2004 10
2005 4
2006 9
2007 14
2008 7
2009 5
2010 5
2011 17
2012 18
2013 13
2014 13
2015 10
2016 5
2017 5
2018 9
2019 4
2020 5
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

194 results
Results by year
Filters applied: . Clear all
Page 1
Targeting myeloid-derived suppressor cells for cancer immunotherapy.
Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, Cha SC, Smith DL, Kwak LW, Qin H. Liu Y, et al. Among authors: kwak lw. Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31. Cancer Immunol Immunother. 2018. PMID: 29855694 Review.
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW. Qin H, et al. Among authors: kwak lw. Sci Transl Med. 2019 Sep 25;11(511):eaaw9414. doi: 10.1126/scitranslmed.aaw9414. Sci Transl Med. 2019. PMID: 31554741 Free PMC article.
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM. Chen R, et al. Among authors: kwak lw. Clin Cancer Res. 2020 Mar 1;26(5):1034-1044. doi: 10.1158/1078-0432.CCR-19-1768. Epub 2019 Dec 6. Clin Cancer Res. 2020. PMID: 31811017 Free PMC article. Clinical Trial.
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohani AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Herrera AF, et al. Among authors: kwak lw. J Clin Oncol. 2017 Jan;35(1):24-31. doi: 10.1200/JCO.2016.68.2740. Epub 2016 Oct 24. J Clin Oncol. 2017. PMID: 28034071 Free PMC article.
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.
Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, Jurczak W, Lopez Martinez A, Samoilova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Ogura M, et al. Among authors: kwak lw. Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1. Lancet Haematol. 2018. PMID: 30389036 Clinical Trial.
Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN. Mohanty A, et al. Among authors: kwak lw. Blood. 2019 Jan 24;133(4):306-318. doi: 10.1182/blood-2018-05-851667. Epub 2018 Dec 10. Blood. 2019. PMID: 30530749 Free PMC article.
Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Oki Y, et al. Among authors: kwak lw. Br J Haematol. 2014 Sep;166(6):891-901. doi: 10.1111/bjh.12982. Epub 2014 Jun 18. Br J Haematol. 2014. PMID: 24943107
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.
Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Alyea EP, Budde LE, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. Herrera AF, et al. Among authors: kwak lw. Biol Blood Marrow Transplant. 2018 Mar;24(3):514-520. doi: 10.1016/j.bbmt.2017.11.023. Epub 2017 Nov 28. Biol Blood Marrow Transplant. 2018. PMID: 29196080 Free PMC article. Clinical Trial.
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Fowler NH, et al. Among authors: kwak lw. Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439689 Free PMC article. Clinical Trial.
194 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page